Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation
Reviewartikel, 2012
Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called - omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes.
filamentous fungi
therapeutic proteins
escherichia-coli
human hemoglobin
human serum-albumin
heterologous proteins
expression
alpha-hemoglobin
pichia-pastoris
saccharomyces-cerevisiae
systems
Författare
Jose Luis Martinez Ruiz
Chalmers, Kemi- och bioteknik, Livsvetenskaper
Lifang Liu
Chalmers, Kemi- och bioteknik, Livsvetenskaper
Dina Petranovic Nielsen
Chalmers, Kemi- och bioteknik, Livsvetenskaper
Jens B Nielsen
Chalmers, Kemi- och bioteknik, Livsvetenskaper
Current Opinion in Biotechnology
0958-1669 (ISSN) 1879-0429 (eISSN)
Vol. 23 6 965-971Industrial Systems Biology of Yeast and A. oryzae (INSYSBIO)
Europeiska kommissionen (EU) (EC/FP7/247013), 2010-01-01 -- 2014-12-31.
Styrkeområden
Livsvetenskaper och teknik (2010-2018)
Ämneskategorier
Kemi
DOI
10.1016/j.copbio.2012.03.011